特发性肺纤维化治疗新进展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

雷凯春 ¹ ,  岳红梅 ² , 周婷婷 ³

1. ;
2. ;
3. ;

Corresponding author：

Keywords：

DOI：

10.7507/1671-6205.201706031

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 雷凯春, 岳红梅, 周婷婷. 特发性肺纤维化治疗新进展. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(2): 199-203. doi: 10.7507/1671-6205.201706031 Copy

1.	Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. J Intern Med, 2016, 281(2): 149-166.
2.	Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA, 2013, 309(21): 2232-2239.
3.	Andersson-Sjöland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol, 2008, 40(10): 2129-2140.
4.	Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J, 2007, 30(5): 835-839.
5.	Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res, 2011, 157(4): 191-199.
6.	Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg, 2003, 126(2): 469-475.
7.	Schaffer JM, Singh SK, Reitz BA, et al. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA, 2015, 313(9): 936-948.
8.	Nishiyama O, Miyajima H, Fukai Y, et al. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia. Respir Med, 2013, 107(8): 1241-1246.
9.	Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med, 2000, 161(4 Pt 1): 1172-1178.
10.	Bendstrup E, Hyldgaard C, Altraja A, et al. Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries. Eur Clin Respir J, 2015, 2(1): 28348.
11.	Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev, 2014, 10(10): 1-55.
12.	Vainshelboim B, Oliveira J, Fox BD, et al. Long-Term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung, 2015, 193(3): 345-354.
13.	Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology, 2011, 16(6): 969-975.
14.	Kohberg C, Andersen CU, Bendstrup E. Opioids: an unexplored option for treatment of dyspnea in IPF. Eur Clin Respir J, 2016, 3: 30629.
15.	Sun T, Liu J, Zhao DW. Efficacy of N-acetylcysteine in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Medicine (Baltimore), 2016, 95(19): 3629-3636.
16.	Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med, 2006, 65(5): 2229-2242.
17.	The Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med, 2012, 366(21): 1968-1977.
18.	The Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of N-acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2093-2101.
19.	Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration, 2014, 88(3): 199-207.
20.	Sakamoto S, Muramatsu Y, Satoh K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology, 2015, 20(3): 445-452.
21.	Homma S, Azuma A, Taniguchi H, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology, 2012, 17(3): 467-477.
22.	Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis,. Am J Respir Crit Care Med, 2015, 192(12): 1475-1482.
23.	Bando M. Pirfenidone: clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis. Respir Investig, 2016, 54(5): 298-304.
24.	Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2005, 171(9): 1040-1047.
25.	Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J, 2010, 35(4): 821-829.
26.	Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, 2011, 377(9779): 1760-1769.
27.	King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2083-2092.
28.	Aravena C, Labarca G, Venegas C, et al. Correction: pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One, 2015, 10(10): 0140288.
29.	Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis, 2014, 31(3): 198-205.
30.	Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2071-2082.
31.	Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med, 2011, 365(12): 1079-1087.
32.	Tomioka H, Takada H. Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis. Respirol Case Rep, 2017, 5(2): e00215.

1. Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. J Intern Med, 2016, 281(2): 149-166.
2. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA, 2013, 309(21): 2232-2239.
3. Andersson-Sjöland A, de Alba CG, Nihlberg K, et al. Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol, 2008, 40(10): 2129-2140.
4. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?. Eur Respir J, 2007, 30(5): 835-839.
5. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res, 2011, 157(4): 191-199.
6. Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg, 2003, 126(2): 469-475.
7. Schaffer JM, Singh SK, Reitz BA, et al. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA, 2015, 313(9): 936-948.
8. Nishiyama O, Miyajima H, Fukai Y, et al. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia. Respir Med, 2013, 107(8): 1241-1246.
9. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med, 2000, 161(4 Pt 1): 1172-1178.
10. Bendstrup E, Hyldgaard C, Altraja A, et al. Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries. Eur Clin Respir J, 2015, 2(1): 28348.
11. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev, 2014, 10(10): 1-55.
12. Vainshelboim B, Oliveira J, Fox BD, et al. Long-Term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. Lung, 2015, 193(3): 345-354.
13. Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology, 2011, 16(6): 969-975.
14. Kohberg C, Andersen CU, Bendstrup E. Opioids: an unexplored option for treatment of dyspnea in IPF. Eur Clin Respir J, 2016, 3: 30629.
15. Sun T, Liu J, Zhao DW. Efficacy of N-acetylcysteine in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Medicine (Baltimore), 2016, 95(19): 3629-3636.
16. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med, 2006, 65(5): 2229-2242.
17. The Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med, 2012, 366(21): 1968-1977.
18. The Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez FJ, de Andrade JA, Anstrom KJ, et al. Randomized trial of N-acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2093-2101.
19. Oltmanns U, Kahn N, Palmowski K, et al. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases. Respiration, 2014, 88(3): 199-207.
20. Sakamoto S, Muramatsu Y, Satoh K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology, 2015, 20(3): 445-452.
21. Homma S, Azuma A, Taniguchi H, et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology, 2012, 17(3): 467-477.
22. Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis,. Am J Respir Crit Care Med, 2015, 192(12): 1475-1482.
23. Bando M. Pirfenidone: clinical trials and clinical practice in patients with idiopathic pulmonary fibrosis. Respir Investig, 2016, 54(5): 298-304.
24. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2005, 171(9): 1040-1047.
25. Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J, 2010, 35(4): 821-829.
26. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, 2011, 377(9779): 1760-1769.
27. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2083-2092.
28. Aravena C, Labarca G, Venegas C, et al. Correction: pirfenidone for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One, 2015, 10(10): 0140288.
29. Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis, 2014, 31(3): 198-205.
30. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 2014, 370(22): 2071-2082.
31. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med, 2011, 365(12): 1079-1087.
32. Tomioka H, Takada H. Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis. Respirol Case Rep, 2017, 5(2): e00215.

Previous Article
变异性通气的原理与应用价值
Next Article
特发性肺纤维化生物标志物的研究进展

Chinese Journal of Respiratory and Critical Care Medicine

特发性肺纤维化治疗新进展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content